Erratum: Effect of folate and mecobalamin on hip fractures in patients with stroke: A randomized controlled trial (JAMA - Journal of the American Medical Association (2005) 293:9 (1082-1088) DOI: 10.1001/jama.293.9.1082);Effect of folate and mecobalamin on hip fractures in patients with stroke: A randomized controlled trial

JAMA

Volumn 293, Issue 9, 2005, Pages 1082-1088

  Sato, Yoshihiro ^a   Honda, Yoshiaki ^a   Iwamoto, Jun ^b   Kanoko, Tomohiro ^c   Satoh, Kei ^c  

^a Mitate Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COBALAMIN; FOLIC ACID; HOMOCYSTEINE; MECOBALAMIN; CYANOCOBALAMIN; DRUG DERIVATIVE;

AGED; ANOREXIA; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLIC ACID BLOOD LEVEL; HEMIPLEGIA; HIP FRACTURE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; BLOOD; BONE DENSITY; CEREBROVASCULAR ACCIDENT; DIET SUPPLEMENTATION; RISK FACTOR;

AGED; BONE DENSITY; CEREBROVASCULAR ACCIDENT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HEMIPLEGIA; HIP FRACTURES; HOMOCYSTEINE; HUMANS; MALE; RISK FACTORS; VITAMIN B 12;

EID: 14144253560     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.10705     Document Type: Erratum

References (41)

1. Ramnemark A, Nyberg L, Borssén B, Olsson T, Gustafson Y. Fractures after stroke. Osteoporos Int. 1998; 8:92-95.
2. Mulley G, Espley AJ. Hip fracture after hemiplegia. Postgrad Med J. 1979;55:264-265.
3. Poplingher AR, Pillar T. Hip fracture in stroke patients. Acta Orthop Scand. 1985;56:226-227.
4. Hooper G. Internal fixation of fractures of the neck of the femur in hemiplegic patients. Injury. 1979;10:281-284.
5. Chiu KY, Pun WK, Luk KDK, Chow SP. A prospective study on hip fractures in patients with previous cerebrovascular accidents. Injury. 1992;23:297-299.
6. Nurmi I, Narinen A, Luthje P, Tanninen S. Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients. Arch Orthop Trauma Surg. 2003;123:551-554.
7. Sato Y, Kaji M, Oizumi K. Vitamin D deficiency and the risk of hip fractures among disabled elderly stroke patients. Stroke. 2001;32:1673-1677.
8. Verhoef P, Hennekens CH, Malinow R, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
9. Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
10. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
11. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke. 2000;31:1069-1075.
12. El Kossi MM, Zakhary MM. Oxidative stress in the context of acute cerebrovascular stroke. Stroke. 2000; 31:1889-1892.
13. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 1989;79:139-146.
14. Bots ML, Launer LJ, Lindemans JL, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999;159:38-44.
15. Brattström L, Israelsson B, Nonving B, et al. Impaired homocysteine metabolism in early-onset and peripheral occlusive arterial disease: effect of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
16. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
17. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004; 291:565-575.
18. Grieco AJ. Homocystinuria: pathogenetic mechanisms. Am J Med Sci. 1977;273:120-132.
19. Morreels CL Jr, Fletcher BD, Weilbaecher RG, Dorst JP. The roentgenographic features of homocystinuria. Radiology. 1968;90:1150-1158.
20. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
21. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033-2041.
22. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350:2042-2049.
23. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. The homocysteine in plasma or serum: methods of clinical applications. Clin Chem. 1993;39:1764-1779.
24. Joosten E, van den Berg A, Riezler R, et al. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr. 1993;58:468-476.
25. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York, NY: Marcel Dekker Inc; 1992:183-236.
26. Sato Y, Kaji M, Kondo I, Satoh K, Metoki N. Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: effect of combined therapy with folic acid and mecobalamine. J Neurol Sci. 2002;202:65-68.
27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61-65.
28. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke. 1985;16:885-890.
29. Matsumoto C, Kushida K, Yamazaki K, Imose K, Inoue T. Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif Tissue Int. 1994;55:324-329.
30. Sato Y, Asoh T, Kaji M, Oizumi K. Benefical effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Miner Res. 2000;15:2487-2494.
31. Sato Y, Metoki N, Iwamoto J, Satoh K. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in stroke patients. Neurology. 2003;61:338-342.
32. Matsui T, Arai H, Yuzuriha T, et al. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke. 2001;32:1116-1119.
33. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
34. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33:522-532.
35. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
36. Browner WS, Malinow MR. Homocys(e)inaemia and bone mineral density in elederly women. Lancet. 1991;338:1470.
37. McKusick VA. Heritable Disorders of Connective Tissue. 3rd ed. St Louis, Mo: Mosby; 1966:155.
38. Jackson SH. The reaction of homocysteine with aldehyde: an explanation of the collagen defects in homocystinuria. Clin Chim Acta. 1973;45:215-217.
39. Sato Y, Maruoka H, Honda Y, Asoh T, Fujimatsu Y, Oizumi K. Development of osteopenia in the hemiplegic finger in patients with stroke. Eur Neurol. 1996;36:278-283.
40. Bainbridge KE, Sowers M, Lin X, Harlow SD. Risk factors for low bone mineral density and the 6-year rate of bone loss among premenopausal and perimenopausal women. Osteoporos Int. 2004;15:439-446.
41. Henderson LB, Adams JS, Goldstein DR, Braunstein GD, Rotter JI, Scheuner MT. A familial risk profile for osteoporosis. Genet Med. 2000;2:222-225.